Drug Profile
Etrolizumab - Genentech
Alternative Names: Monoclonal antibody beta7; PRO-145223; recombinant-human-monoclonal-antibody-beta7; RG 7413; rhu-monoclonal-antibody-beta7; rhuMAb Beta7; rhuMAb β7; RO 5490261Latest Information Update: 10 Oct 2024
Price :
$50
*
At a glance
- Originator Genentech
- Developer Genentech; Roche
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Alpha4beta7 integrin antagonists; Integrin alphaEbeta7 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease; Ulcerative colitis
Most Recent Events
- 30 Sep 2024 Genentech completes a phase III clinical trials in Ulcerative colitis (Combination therapy, Treatment-experienced) in Slovenia (SC) (EudraCT2019-004652-11)
- 09 Oct 2023 Roche terminates a phase III extension JUNIPER trial for Crohn's disease in Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Croatia, Czechia, Estonia, France, Germany, Hungary, Israel, Italy, South Korea, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Russia, Serbia, Solvakia, Sweden, South Africa, Spain, Switzerland, Turkey, Ukraine, US and United Kingdom due to program discontinuation, based on mixed efficacy results in the parent studies and there were no safety concerns observed (NCT02403323)
- 27 Sep 2023 Roche terminates phase-I FENNEL trial in Crohn's disease (In children, In adolescents) in Spain, Poland, Belgium, Germany and United Kingdom (SC) due to program discontinuation based on mixed efficacy results (NCT03478956) (EudraCT2017-003649-10)